The vaccine experiment Epstein-Barr virus (EBV) achieves “promising” results in mice, according to a preliminary study published in the journal Nature Communications. This scientific progress, although still under development, is of great interest to study the causal relationship between EBV and multiple sclerosis.
“There is a global need for new advances,” says a paper signed by researchers at the Berghofer Medical Research Institute in Australia, as no vaccine has been approved to protect against this virus, which infects at least 95% of the world’s population. according to EFE.
Previously, other vaccines have not performed well in human and animal models. This vaccine is now targeted at lymph node, Open a ray of hope then “showed promising results in mice”.
Encouraging Milestone: Specific Antibodies
The researchers responsible for developing the vaccine found that when administered to these animals, it “strong” specific antibodies are produced EBV and T cells that have persisted for at least seven months after vaccination.
In addition, scientists remind that the way to create this vaccine “actually prevent multiple sclerosis“and is able to “induce immunity” to control tumors associated with the virus.
The research team will continue to work on the design of this vaccine to ensure that effective results in mice are also obtained in humans.
A virus from the herpes family is transmitted through saliva and can cause mononucleosis, better known as “kissing disease” and may be a risk factor for other diseases such as throat and nose cancer or multiple sclerosis, more and more research suggests that infection may be a precursor to this disease. The immune system does not eliminate the Esptein-Barr virus from the body, so it can be reactivated and transmitted again.
The possibility that infection with the “kissing disease” virus plays a role in the development of multiple sclerosis was one of the big advances of 2022 that Science cites.